NEW YORK, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for ...
Data from first adult patient dosed in REVEAL Phase 1/2 trial showed TSHA-102 was well-tolerated with no treatment-emergent serious adverse events (SAEs) as of six-week assessment and improvement in ...
Emiliana was an easygoing baby and a happy toddler who loved to smile, but her parents could tell something wasn’t right. She was late to learn to walk and when she was about 18 months old, they ...
Taysha Gene Therapies, Inc. ((TSHA)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert ...
Available clinical data from the two adult patients dosed with TSHA-102 in the first cohort (low dose) to be discussed during upcoming quarterly earnings call following Independent Data Monitoring ...
Credit: Getty Images. TSHA-102 is an investigational adeno-associated virus 9 gene transfer therapy. The Food and Drug Administration (FDA) has granted Fast Track designation to TSHA-102 for the ...
A new UC Davis MIND Institute study offers critical insights into Rett syndrome, a rare genetic condition that affects mostly girls. The research reveals how this condition affects males and females ...
Rett syndrome is a rare developmental disorder, most often due to a mutation in the MECP2 gene on the X chromosome, but it’s not usually inherited. Advances in genetics have launched a new era in ...
--DAYBUE is the first and only therapy approved in Canada for the treatment of Rett syndrome, a rare, neurodevelopmental disorder SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) ...
Acadia Pharmaceuticals ACAD announced that it expects to receive a negative opinion from the European Medicines Agency’s (EMA ...
Company expects to receive a negative opinion following oral explanation feedback and intends to request re-examination upon review of formal adoption. Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results